Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

818
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
818
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

2.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neurogranin Promotes Neuronal Maturation and Network Activity Through Ca<sup>2+</sup>/Calmodulin Signaling.

International journal of molecular sciences·2026
Same author

Resilience and susceptibility to fear extinction are associated with alterations in neurogenesis and brain-wide activity.

Neurobiology of disease·2026
Same author

Sex hormones and diets rich in polyunsaturated ω-6/ω-3 fatty acids modify microbiota distinctly in a mouse model of Alzheimer's disease.

Gut microbiome (Cambridge, England)·2025
Same author

Sphingomyelin-induced glucocorticoid receptor alterations lead to impaired presynaptic plasticity in acid sphingomyelinase deficient neurons.

Neurobiology of disease·2025
Same author

Exploring individual differences in fear extinction in male and female mice: insights from HPA axis, microbiota, and transcriptomics.

Translational psychiatry·2025
Same author

Long-term consequences of adolescent exposure to the synthetic cannabinoid AB-FUBINACA in male and female mice.

iScience·2025

Related Experiment Video

Updated: Mar 27, 2026

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-&#946; and Tau Neuropathology
10:02

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Published on: May 28, 2017

28.4K

PTEN recruitment controls synaptic and cognitive function in Alzheimer's models.

Shira Knafo1,2,3, Cristina Sánchez-Puelles1, Ernest Palomer1

  • 1Department of Molecular Neurobiology, Centro de Biología Molecular "Severo Ochoa", Consejo Superior de Investigaciones Científicas (CSIC) / Universidad Autónoma de Madrid, Madrid, Spain.

Nature Neuroscience
|January 19, 2016
PubMed
Summary

In Alzheimer's disease, amyloid-β peptide (Aβ) impairs synaptic function. Inhibiting PTEN, a key enzyme, restored normal cognition and synaptic plasticity in models, revealing a new therapeutic target.

More Related Videos

Intracerebroventricular Injection of Amyloid-&#946; Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
08:01

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Published on: March 16, 2016

45.0K
Fabrication of Amyloid-&#946;-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
06:52

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease

Published on: July 6, 2019

9.8K

Related Experiment Videos

Last Updated: Mar 27, 2026

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-&#946; and Tau Neuropathology
10:02

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Published on: May 28, 2017

28.4K
Intracerebroventricular Injection of Amyloid-&#946; Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
08:01

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Published on: March 16, 2016

45.0K
Fabrication of Amyloid-&#946;-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
06:52

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease

Published on: July 6, 2019

9.8K

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Biochemistry

Background:

  • Amyloid-β peptide (Aβ) dyshomeostasis is implicated in Alzheimer's disease (AD) pathogenesis, causing synaptic dysfunction and cognitive decline.
  • Aβ disrupts synaptic plasticity, favoring long-term depression (LTD), a cellular mechanism underlying memory formation.

Purpose of the Study:

  • To investigate the role of the lipid phosphatase PTEN in Aβ-induced synaptic malfunction.
  • To identify the molecular mechanisms by which Aβ affects PTEN and synaptic function.

Main Methods:

  • Utilized cellular and animal models of Alzheimer's disease.
  • Employed PTEN inhibition and overexpression strategies.
  • Investigated Aβ-induced PTEN recruitment to the postsynaptic compartment using a PTEN knock-in mouse model lacking the PDZ motif and cell-permeable interfering peptides.

Main Results:

  • Inhibition of PTEN rescued synaptic function and cognition in AD models.
  • Overexpression of PTEN induced synaptic depression mimicking Aβ effects.
  • Aβ triggers PDZ-dependent postsynaptic recruitment of PTEN, a critical step in Aβ-induced synaptic toxicity and cognitive deficits.

Conclusions:

  • PTEN plays a crucial role in mediating Aβ-induced synaptic depression and cognitive impairment in Alzheimer's disease.
  • Targeting the Aβ-PTEN interaction offers a potential therapeutic strategy for Alzheimer's disease.